Olema Cash Falls To $413.8 Million From $505.4 Million Ahead Of Pivotal Cancer Results
Research expenses rose to $67.6 million as Olema funded breast-cancer trials and prepared for potential commercialization.
Olema Pharmaceuticals, which is testing palazestrant for advanced breast cancer, ended the third quarter with cash and investments of $413.8 million, down from $505.4 million at year-end 2025. The company reported results Tuesday, with pivotal results for palazestrant expected in the first quarter of 2027.
The Cost Of Expanding Trials
Olema's quarterly research expenses reached $67.6 million, compared with $40.0 million a year earlier. The company attributed the increase mainly to enrollment in its late-stage palazestrant trials, work on OP-3136, manufacturing and clinical supplies, and additional personnel costs.
Removing noncash stock compensation leaves research expenses of $59.9 million, versus $37.4 million. Stock compensation within research expenses rose to $7.7 million from $2.6 million; Olema attributed that increase mainly to higher grant prices and a larger workforce.
Administrative expenses reached $9.9 million, up from $5.9 million. That included $4.4 million in noncash stock compensation, versus $1.7 million; excluding it, administrative expenses were $5.5 million, compared with $4.3 million. Olema tied the increase to staffing, corporate infrastructure and preparations for a possible palazestrant launch, including a $1.0 million increase in professional fees.
The quarterly net loss widened to $73.6 million, or $0.73 a share, from $42.2 million, or $0.49 a share. For the first nine months, Olema lost $189.9 million, or $1.89 a share, compared with $116.4 million, or $1.36 a share, a year earlier.
Palazestrant Approaches Its Pivotal Readout
Olema has no approved products and has earned no revenue from product sales. Its lead candidate is an oral drug being studied in breast cancer that is estrogen-receptor positive and HER2 negative, including disease that has returned, advanced locally or spread.
The pivotal OPERA-01 trial tests palazestrant alone. OPERA-02 pairs it with Novartis's ribociclib as an initial treatment for metastatic breast cancer.
“Enrollment is accelerating, investigator interest is strong, and patients with frontline disease continue to require better therapeutic options,” Olema President and Chief Executive Officer Sean P. Bohen said of the combination trial.
Palazestrant has FDA Fast Track designation for certain patients whose metastatic breast cancer progressed after endocrine therapy. Olema owns worldwide development and commercialization rights to palazestrant and OP-3136 and uses outside manufacturers for both.
The company appointed Jason O’Byrne chief financial officer in August as it prepared for pivotal results and potential commercialization.
Combination Studies Beyond The Pivotal Trials
OP-3136 targets KAT6, an enzyme implicated in breast and other cancers. Olema plans to start enrolling patients during the fourth quarter in an early-stage study pairing it with darolutamide for metastatic castration-resistant prostate cancer, in collaboration with Bayer.
Last Wednesday, Olema announced combination-data presentations for December's San Antonio Breast Cancer Symposium. Those cover OP-3136 with fulvestrant and palazestrant with either everolimus or atirmociclib in advanced or metastatic estrogen-receptor-positive, HER2-negative breast cancer.
Olema also plans to present preclinical findings on selective KAT6A degradation in estrogen-receptor-positive breast cancer at November's EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
The main clinical milestone remains the OPERA-01 readout, which Olema expects in the first quarter of 2027.
Sources
- 8-K Filing — Olema Pharmaceuticals, Inc. (OLMA) — SEC EDGAR
- Exhibit olma-ex99_1.htm — Olema Pharmaceuticals, Inc. 8-K exhibit — SEC EDGAR
- Olema Oncology to Present Combination Data from the — globenewswire.com
- 8-K filed 2026-08-13 — Olema Pharmaceuticals, Inc. (earlier disclosure) — SEC EDGAR